Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 126
interventional 89
Observational 28
Registry 9

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 36
Drug|placebo 31
Biological 4
Behavioral 3
Biological|placebo 3
Device 3
Genetic 2
Other 2
Procedure 2
Dietary Supplement 1
Dietary Supplement|Other 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
NA 12
United States 6
Canada 3
China 3
France 2
Japan 2
Netherlands 2
Norway 2
United States|Brazil|Canada|Singapore|South Africa|Taiwan|United Kingdom 2
United States|Canada|Germany|Netherlands|United Kingdom 2
United States|Canada|Italy|South Africa 2
United States|Netherlands 2
Australia|New Zealand 1
Austria 1
Belgium|Canada|Denmark|Israel|Malaysia|Netherlands|Taiwan 1
Belgium|Canada|Denmark|Israel|Malaysia|Taiwan 1
Brazil|Canada|Denmark|Mexico|Netherlands|Russian Federation|Slovenia|Spain|Taiwan|Turkey 1
Canada|France|Netherlands|Norway 1
Canada|Greece|Norway 1
Czech Republic|Netherlands|Norway|United Kingdom 1
Denmark 1
France|Germany|Netherlands|Sweden|United Kingdom 1
Germany 1
Hong Kong|Israel|Russian Federation|Serbia|South Africa|Taiwan|Turkey|Ukraine 1
Hungary|India|Israel|Italy|United States|Argentina|Australia|Belgium|Brazil|Canada|Croatia|Czechia|Denmark|Germany|Greece|Hong Kong|Korea, Republic of|Malaysia|Netherlands|New Zealand|Norway|Poland|Russian Federation|South Africa|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
India 1
Iran, Islamic Republic of 1
Israel|Italy|Japan|Lebanon|Netherlands|United States|Australia|Belgium|Brazil|Canada|Czechia|France|Greece|Hong Kong|New Zealand|South Africa|Spain|United Kingdom 1
Mexico 1
Switzerland 1
Ukraine|Poland|Italy 1
United Kingdom 1
United States|Argentina|Austria|Brazil|Bulgaria|Canada|Czechia|Denmark|Finland|France|Hungary|Italy|Lebanon|Mexico|Netherlands|Norway|Poland|Russian Federation|Slovenia|South Africa|Spain|Sweden|Taiwan|Turkey 1
United States|Australia|Austria|Belgium|Brazil|Canada|Colombia|Czechia|Finland|Greece|Hungary|Italy|Malaysia|Netherlands|New Zealand|Norway|Poland|Portugal|Russian Federation|Slovenia|South Africa|Spain|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Canada|Colombia|Czechia|Greece|Hungary|Italy|Malaysia|Netherlands|Norway|Poland|Portugal|Russian Federation|Slovenia|South Africa|Spain|Switzerland|Turkey|United Kingdom 1
United States|Australia|Austria|Canada|Czechia|France|Greece|Italy|Japan|Netherlands|South Africa|Ukraine 1
United States|Australia|Austria|Canada|France|Greece|Italy|Japan|Netherlands|South Africa|Ukraine 1
United States|Australia|Canada|Denmark|France|Iceland|Norway|South Africa|Sweden| 1
United States|Australia|Canada|France|Germany|Hong Kong|Netherlands|New Zealand|Norway|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Austria|Canada|Czech Republic|Denmark|France|Israel|Netherlands|Norway|Russian Federation|South Africa|Spain|Sweden|United Kingdom 1
United States|Austria|Canada|Czechia|France|Germany|Greece|Italy|Japan|South Africa|Taiwan|Turkey|Ukraine 1
United States|Belgium|Canada|Czechia|France|Hong Kong|Italy|Lebanon|Netherlands|New Zealand|South Africa|Spain 1
United States|Belgium|Canada|Germany|Greece|Hungary|Italy|Norway|Poland|Puerto Rico|Russian Federation|Slovakia|Spain|Switzerland|Turkey 1
United States|Belgium|Canada|Netherlands|Norway 1
United States|Bulgaria|Canada|Finland|Italy|Netherlands|Norway|Poland|South Africa|Spain|United Kingdom 1
United States|Canada 1
United States|Canada|Czech Republic|Finland|France|Italy|Netherlands|South Africa 1
United States|Canada|Czechia|Denmark|Germany|Hungary|Netherlands|Poland|South Africa|Spain|Sweden|Ukraine|United Kingdom 1
United States|Canada|Czechia|Denmark|Netherlands|South Africa|Spain|Sweden 1
United States|Canada|Czechia|France|Netherlands|Norway|Russian Federation|South Africa|Spain|Sweden 1
United States|Canada|Israel 1
United States|Canada|Italy|Netherlands 1
United States|Canada|Italy|Netherlands|United Kingdom 1
United States|Canada|Netherlands 1
United States|Canada|Netherlands|Norway|Spain 1
United States|Canada|Netherlands|Russian Federation|South Africa 1
United States|Canada|South Africa 1
United States|France 1
United States|Germany 1
United States|Israel|Norway|South Africa|Turkey 1
United States|Netherlands|South Africa 1

Sites per Study

Site_count Study_Count
1 32
2 2
3 3
4 1
5 3
6 5
7 1
8 3
9 3
10 4
11 1
12 2
13 2
14 1
16 1
20 1
21 1
26 1
28 1
30 1
32 1
33 1
35 2
37 1
39 1
41 2
44 1
45 1
46 1
47 1
48 1
52 1
54 1
66 1
88 1
91 1
116 1
240 1

Phase

Phase Study_Count
Phase 3 43
Phase 2 20
N/A 10
Phase 4 5
Phase 1 4
Phase 1/Phase 2 3
Phase 2/Phase 3 3
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 27
2 35
3 7
4 8
5 1
6 1
8 2
11 1
NA 7

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 705 6.00 1.00 12.00000 6.00 30.0000 9.0000 22
1st Qu. 705 22.75 4.00 26.00000 11.50 44.0000 52.2500 30
Median 705 56.00 22.00 40.00000 32.50 58.0000 129.5000 86
Mean 705 2547.80 34.75 33.33333 104.15 129.3333 235.0476 117
3rd Qu. 705 375.00 52.75 44.00000 158.25 179.0000 266.2500 113
Max. 705 24000.00 94.00 48.00000 501.00 300.0000 2991.0000 334

Trial Group Type

group_type Group_Count
Experimental 129
Placebo Comparator 36
Active Comparator 12
Other 10
NA 7
No Intervention 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 47
Single Group Assignment 30
Crossover Assignment 7
Sequential Assignment 2
NA 2
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 79
Prevention 3
Diagnostic 2
Other 2
Health Services Research 1
Screening 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
NA 8
United States 6
Canada 3
Italy 2
Spain 2
China 1
Germany 1
Germany|India|Sri Lanka 1
Japan 1
Sweden 1
Turkey 1
United Arab Emirates 1

Sites per Study

Site_count Study_Count
1 21
2 2
3 1
4 1
11 1
81 1
139 1

Enrollment Metrics

Measure Observational
Min 5.000
1st Qu 80.000
Median 400.000
Mean 7200.519
3rd Qu 2794.500
Max 150000.000

Observation Model

observational_model Study_Count
Cohort 14
Case-Only 5
NA 4
Case-Control 1
Case-Crossover 1
Case Control 1
Ecologic or Community 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 21
Cross-Sectional 4
Retrospective 2
NA 1

Registries

Studies by Country

Country Study_Count
Iran, Islamic Republic of 2
United States 2
Canada 1
Greece 1
NA 1
Russian Federation 1
United Kingdom 1

Sites per Study

Site_count Study_Count
1 8
5 1

Enrollment Metrics

Measure Registries
Min 300.0
1st Qu 500.0
Median 1000.0
Mean 190249.8
3rd Qu 6000.0
Max 1622948.0

Registry Model

observational_model Study_Count
Cohort 7
Other 1
NA 1

Time Perspective

time_perspective Study_Count
Prospective 7
Cross-Sectional 1
NA 1

Follow-up

target_duration Study_Count
10 Years 3
5 Years 3
1 Month 1
15 Years 1
3 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04031742 A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT04031742 Recruiting Innovent Biologics (Suzhou) Co. Ltd. 2021-01-13
NCT03409744 Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT03409744 Enrolling by invitation Regeneron Pharmaceuticals 2022-04-18
NCT03397121 Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) https://ClinicalTrials.gov/show/NCT03397121 Active, not recruiting The Medicines Company 2019-09-27
NCT03331666 Impact of LDL-cholesterol Lowering on Platelet Activation https://ClinicalTrials.gov/show/NCT03331666 Recruiting Columbia University 2021-07-01
NCT03234127 Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia https://ClinicalTrials.gov/show/NCT03234127 Recruiting Nantes University Hospital 2020-11-30
NCT03156621 Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) https://ClinicalTrials.gov/show/NCT03156621 Completed Regeneron Pharmaceuticals 2019-09-27
NCT03135184 HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT03135184 Active, not recruiting HDL Therapeutics 2019-01-07
NCT03060577 An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol https://ClinicalTrials.gov/show/NCT03060577 Active, not recruiting The Medicines Company 2018-08-29
NCT03038022 Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) https://ClinicalTrials.gov/show/NCT03038022 Completed Madrigal Pharmaceuticals, Inc. 2017-12-18
NCT02963311 A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH) https://ClinicalTrials.gov/show/NCT02963311 Completed The Medicines Company 2018-10-08
NCT02890992 An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT02890992 Completed Sanofi 2018-09-13
NCT02748057 A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833) https://ClinicalTrials.gov/show/NCT02748057 Completed Merck Sharp & Dohme Corp. 2017-12-11
NCT02729857 Postprandial Response After Intake of Meals With Different Fatty Acid Composition https://ClinicalTrials.gov/show/NCT02729857 Completed University of Oslo 2016-06-30
NCT02722408 Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1) https://ClinicalTrials.gov/show/NCT02722408 Completed NeuroBo Pharmaceuticals Inc. 2017-04-30
NCT02709850 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT02709850 Completed Ionis Pharmaceuticals, Inc. 2017-04-12
NCT02651675 A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH) https://ClinicalTrials.gov/show/NCT02651675 Active, not recruiting Regenxbio Inc. 2022-07-31
NCT02624869 Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH). https://ClinicalTrials.gov/show/NCT02624869 Active, not recruiting Amgen 2021-06-07
NCT02597127 Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) https://ClinicalTrials.gov/show/NCT02597127 Completed The Medicines Company 2017-06-07
NCT03403374 Safety and Tolerability of Repatha in Indian Subjects With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT03403374 Completed Amgen 2019-11-27
NCT03399786 Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT03399786 Completed Regeneron Pharmaceuticals 2019-06-10
NCT02472535 Study to Evaluate the Effects of MBX-8025 in Patients With HoFH https://ClinicalTrials.gov/show/NCT02472535 Completed CymaBay Therapeutics, Inc. 2016-02-29
NCT02462655 Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT02462655 Completed Laval University 2015-12-31
NCT02460159 A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384) https://ClinicalTrials.gov/show/NCT02460159 Completed Merck Sharp & Dohme Corp. 2016-12-22
NCT02434497 A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT02434497 Completed AstraZeneca 2016-11-17
NCT02392559 Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders https://ClinicalTrials.gov/show/NCT02392559 Completed Amgen 2019-11-25
NCT02326220 Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy https://ClinicalTrials.gov/show/NCT02326220 Completed Regeneron Pharmaceuticals 2016-01-31
NCT02265952 Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) https://ClinicalTrials.gov/show/NCT02265952 Completed Regeneron Pharmaceuticals 2016-11-21
NCT02226198 A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT02226198 Completed AstraZeneca 2015-07-31
NCT02173158 Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy https://ClinicalTrials.gov/show/NCT02173158 Completed Aegerion Pharmaceuticals, Inc. 2015-04-03
NCT02107898 Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN) https://ClinicalTrials.gov/show/NCT02107898 Completed Sanofi 2015-01-31
NCT02048410 Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT02048410 Completed Federico II University 2012-09-30
NCT01995149 Effect of Weight Loss on Cholesterol Metabolism in Hereditary Hypercholesterolemias and Overweight or Obesity. https://ClinicalTrials.gov/show/NCT01995149 Completed Instituto Aragones de Ciencias de la Salud 2012-09-30
NCT01824238 A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) https://ClinicalTrials.gov/show/NCT01824238 Completed Merck Sharp & Dohme Corp. 2014-05-31
NCT01813006 Effect of Omega-3 Fatty Acid on Endothelial Function https://ClinicalTrials.gov/show/NCT01813006 Completed Nordlandssykehuset HF 2016-12-31
NCT01763918 Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 https://ClinicalTrials.gov/show/NCT01763918 Completed Amgen 2013-11-27
NCT01709500 Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) https://ClinicalTrials.gov/show/NCT01709500 Completed Regeneron Pharmaceuticals 2014-05-31
NCT01624142 Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders https://ClinicalTrials.gov/show/NCT01624142 Completed Amgen 2018-05-11
NCT01623115 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy https://ClinicalTrials.gov/show/NCT01623115 Completed Sanofi 2014-04-30
NCT01617655 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH) https://ClinicalTrials.gov/show/NCT01617655 Completed Sanofi 2014-05-31
NCT01604824 A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene https://ClinicalTrials.gov/show/NCT01604824 Completed Regeneron Pharmaceuticals 2014-06-02
NCT01588496 Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities https://ClinicalTrials.gov/show/NCT01588496 Completed Amgen 2014-01-31
NCT01556906 Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor https://ClinicalTrials.gov/show/NCT01556906 Completed Aegerion Pharmaceuticals, Inc. 2004-02-29
NCT01524289 Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) https://ClinicalTrials.gov/show/NCT01524289 Completed Merck Sharp & Dohme Corp. 2014-02-12
NCT01515241 Exploratory Study of Plaque Regression https://ClinicalTrials.gov/show/NCT01515241 Completed Cerenis Therapeutics, SA 2012-04-30
NCT01475825 A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol https://ClinicalTrials.gov/show/NCT01475825 Completed Kastle Therapeutics, LLC 2015-12-29
NCT01412034 Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects https://ClinicalTrials.gov/show/NCT01412034 Completed Cerenis Therapeutics, SA 2013-10-31
NCT01388816 A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels https://ClinicalTrials.gov/show/NCT01388816 Completed Dr. Reddy’s Laboratories Limited 2012-05-31
NCT01375751 Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study https://ClinicalTrials.gov/show/NCT01375751 Completed Amgen 2012-05-16
NCT04179669 Safety and Efficacy of IBI306 in HeFH Patients https://ClinicalTrials.gov/show/NCT04179669 Recruiting Innovent Biologics (Suzhou) Co. Ltd. 2022-12-31
NCT04118348 Evaluating the Efficacy of Pediatric Lipid Screening Alerts https://ClinicalTrials.gov/show/NCT04118348 Enrolling by invitation Geisinger Clinic 2020-10-31
NCT03934320 Improving Identification of Familial Hypercholesterolaemia in Primary Care (FAMCAT) https://ClinicalTrials.gov/show/NCT03934320 Enrolling by invitation University of Nottingham 2020-07-31
NCT03933293 A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH https://ClinicalTrials.gov/show/NCT03933293 Recruiting Akeso 2021-02-28
NCT03885921 Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019) https://ClinicalTrials.gov/show/NCT03885921 Completed Merck Sharp & Dohme Corp. 2003-07-08
NCT03884452 Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018) https://ClinicalTrials.gov/show/NCT03884452 Completed Merck Sharp & Dohme Corp. 2001-05-24
NCT03851705 A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) https://ClinicalTrials.gov/show/NCT03851705 Active, not recruiting The Medicines Company 2020-03-02
NCT03832985 Pediatric Reporting of Adult-Onset Genomic Results https://ClinicalTrials.gov/show/NCT03832985 Recruiting Geisinger Clinic 2023-06-30
NCT03814187 Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C https://ClinicalTrials.gov/show/NCT03814187 Active, not recruiting The Medicines Company 2023-08-31
NCT03795038 Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI https://ClinicalTrials.gov/show/NCT03795038 Recruiting Fresenius Medical Care Deutschland GmbH 2019-12-31
NCT03747224 Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients https://ClinicalTrials.gov/show/NCT03747224 Recruiting Arrowhead Pharmaceuticals 2020-05-30
NCT03563547 Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT03563547 Completed Austrian Academic Institute for Clinical Nutrition 2014-10-09
NCT03510884 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT03510884 Recruiting Sanofi 2020-08-18
NCT03510715 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT03510715 Completed Sanofi 2020-02-17
NCT03501875 Study of Coronary Calcification in Subjects With Autosomal Dominant Familial Hypercholesterolemia Heterozygous https://ClinicalTrials.gov/show/NCT03501875 Active, not recruiting Assistance Publique - Hôpitaux de Paris 2021-02-01
NCT01078675 An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia https://ClinicalTrials.gov/show/NCT01078675 Completed AstraZeneca 2013-02-28
NCT00943306 Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00943306 Completed Aegerion Pharmaceuticals, Inc. 2012-09-17
NCT00916643 Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy https://ClinicalTrials.gov/show/NCT00916643 Completed B. Braun Medical Inc. 2009-09-30
NCT04034485 Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH https://ClinicalTrials.gov/show/NCT04034485 Enrolling by invitation LIB Therapeutics LLC 2021-03-31
NCT00827606 Atorvastatin Three Year Pediatric Study https://ClinicalTrials.gov/show/NCT00827606 Completed Pfizer 2013-10-31
NCT01968980 A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT01968980 Completed Pfizer 2016-04-15
NCT00739999 8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00739999 Completed Pfizer 2009-05-31
NCT00730236 A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) https://ClinicalTrials.gov/show/NCT00730236 Completed Aegerion Pharmaceuticals, Inc. 2010-09-30
NCT00706849 Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease https://ClinicalTrials.gov/show/NCT00706849 Completed Kastle Therapeutics, LLC 2009-12-31
NCT00694109 An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00694109 Completed Kastle Therapeutics, LLC 2014-09-30
NCT00688896 Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia https://ClinicalTrials.gov/show/NCT00688896 Completed Akros Pharma Inc. 2003-04-30
NCT00686010 Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia https://ClinicalTrials.gov/show/NCT00686010 Completed Japan Tobacco Inc. 2001-01-31
NCT00655265 A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication https://ClinicalTrials.gov/show/NCT00655265 Completed Sanofi 2008-12-31
NCT00607373 Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00607373 Completed Kastle Therapeutics, LLC 2009-03-31
NCT00515307 Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00515307 Completed University of Tehran 2008-05-31
NCT00477594 Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00477594 Completed Kastle Therapeutics, LLC 2011-03-31
NCT00473655 Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients https://ClinicalTrials.gov/show/NCT00473655 Completed AstraZeneca 2009-02-28
NCT00355615 PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin https://ClinicalTrials.gov/show/NCT00355615 Completed AstraZeneca 2008-07-31
NCT00281008 Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy https://ClinicalTrials.gov/show/NCT00281008 Completed Kastle Therapeutics, LLC 2007-07-31
NCT00280995 Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy https://ClinicalTrials.gov/show/NCT00280995 Completed Kastle Therapeutics, LLC 2007-04-30
NCT00171236 Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00171236 Completed Novartis 2005-03-31
NCT00136981 Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. https://ClinicalTrials.gov/show/NCT00136981 Completed Pfizer NA
NCT00134511 Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder https://ClinicalTrials.gov/show/NCT00134511 Completed Pfizer NA
NCT00134485 Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia https://ClinicalTrials.gov/show/NCT00134485 Completed Pfizer NA
NCT00004809 Phase I Study of Ex Vivo Liver-Directed Gene Therapy for Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00004809 Completed Office of Rare Diseases (ORD) NA
NCT00000594 NHLBI Type II Coronary Intervention Study https://ClinicalTrials.gov/show/NCT00000594 Completed National Heart, Lung, and Blood Institute (NHLBI) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03253432 IN-TANDEM Familial Hypercholesterolemia Pilot Study https://ClinicalTrials.gov/show/NCT03253432 Completed University of Pennsylvania 2018-11-07
NCT03198897 Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH) https://ClinicalTrials.gov/show/NCT03198897 Active, not recruiting Centogene AG Rostock 2021-06-30
NCT03110250 Familial Hypercholesterolemia in Turkey (A-HIT2) https://ClinicalTrials.gov/show/NCT03110250 Completed Ege University 2017-11-30
NCT03018678 Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT03018678 Completed University of Pennsylvania 2017-05-30
NCT02976818 Lp(a) and Aortic Valve Calcification https://ClinicalTrials.gov/show/NCT02976818 Completed Laval University 2019-10-31
NCT02808403 Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan https://ClinicalTrials.gov/show/NCT02808403 Recruiting Amgen 2022-04-30
NCT02750527 Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany https://ClinicalTrials.gov/show/NCT02750527 Enrolling by invitation Kinderkrankenhaus auf der Bult 2020-12-31
NCT02693548 The Spanish Familial Hypercholesterolaemia Cohort Study https://ClinicalTrials.gov/show/NCT02693548 Recruiting Fundación Hipercolesterolemia Familiar 2020-10-31
NCT02286596 Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT02286596 Completed Laval University 2013-06-30
NCT02225340 Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT02225340 Completed Laval University 2014-04-30
NCT01878604 Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT01878604 Completed Central South University 2014-10-31
NCT01753232 Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter https://ClinicalTrials.gov/show/NCT01753232 Completed Fresenius Medical Care Deutschland GmbH 2014-12-31
NCT04080050 A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501 https://ClinicalTrials.gov/show/NCT04080050 Enrolling by invitation Regenxbio Inc. 2024-09-29
NCT04370899 Early Detection of Familial Hypercholesterolemia in Children https://ClinicalTrials.gov/show/NCT04370899 Recruiting Institut Investigacio Sanitaria Pere Virgili 2023-03-14
NCT04313270 Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab® https://ClinicalTrials.gov/show/NCT04313270 Recruiting Federico II University 2022-12-01
NCT04148001 Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients https://ClinicalTrials.gov/show/NCT04148001 Active, not recruiting Regenxbio Inc. 2020-12-30
NCT03640234 Return of Actionable Variants Empirical Study https://ClinicalTrials.gov/show/NCT03640234 Enrolling by invitation Mayo Clinic 2020-06-30
NCT03597958 Genetic Causes of Hypercholesterolaemia in the Emirati Population https://ClinicalTrials.gov/show/NCT03597958 Recruiting Imperial College London Diabetes Centre 2020-12-31
NCT03520140 Prevalence of Familial Hypercholesterolaemia (FH) in Italian Patients With Coronary Artery Disease https://ClinicalTrials.gov/show/NCT03520140 Completed Heart Care Foundation 2018-05-30
NCT01138371 Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers https://ClinicalTrials.gov/show/NCT01138371 Completed Emory University 2012-02-29
NCT01109368 The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository https://ClinicalTrials.gov/show/NCT01109368 Recruiting The Rogosin Institute 2025-05-31
NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) https://ClinicalTrials.gov/show/NCT01107743 Completed Pfizer 2012-04-30
NCT01070966 Vytorin Reexamination Study (0653A-174) https://ClinicalTrials.gov/show/NCT01070966 Completed Merck Sharp & Dohme Corp. 2010-04-30
NCT04101149 Genetic Causes of Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT04101149 Recruiting Region Örebro County 2025-12-31
NCT00705211 A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245) https://ClinicalTrials.gov/show/NCT00705211 Completed Merck Sharp & Dohme Corp. 2009-12-31
NCT00704535 Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED) https://ClinicalTrials.gov/show/NCT00704535 Completed Merck Sharp & Dohme Corp. 2008-04-30
NCT00704444 A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244) https://ClinicalTrials.gov/show/NCT00704444 Completed Merck Sharp & Dohme Corp. 2009-09-30
NCT00005168 Hyperapo B and Coronary Heart Disease https://ClinicalTrials.gov/show/NCT00005168 Completed National Heart, Lung, and Blood Institute (NHLBI) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03140605 Greek Registry - Familial Hypercholesterolaemia https://ClinicalTrials.gov/show/NCT03140605 Recruiting Hellenic College of Treatment of Atherosclerosis 2020-04-10
NCT02870660 Familial Hypercholesterolemia Amongst Patients With Acute Coronary Syndrome https://ClinicalTrials.gov/show/NCT02870660 Recruiting Isfahan University of Medical Sciences 2018-09-30
NCT02865694 Developing and Implementing Familial Hypercholesterolemia Registry https://ClinicalTrials.gov/show/NCT02865694 Recruiting Isfahan University of Medical Sciences 2017-09-30
NCT02778646 Detection of Familial Hypercholesterolaemia in Cardiovascular Disease Registry https://ClinicalTrials.gov/show/NCT02778646 Completed University College, London 2014-12-31
NCT02208869 Russian Familial Hypercholesterolemia Registry https://ClinicalTrials.gov/show/NCT02208869 Recruiting Russian Cardiology Research and Production Center 2017-12-31
NCT02135705 LOWER: Lomitapide Observational Worldwide Evaluation Registry https://ClinicalTrials.gov/show/NCT02135705 Enrolling by invitation Aegerion Pharmaceuticals, Inc. 2028-03-31
NCT02009345 Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada https://ClinicalTrials.gov/show/NCT02009345 Recruiting McGill University Health Centre/Research Institute of the McGill University Health Centre 2016-11-30
NCT01960244 Study of Awareness and Detection of Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT01960244 Recruiting The Familial Hypercholesterolemia Foundation 2020-12-31
NCT04272697 EAS Familial Hypercholesterolaemia Studies Collaboration https://ClinicalTrials.gov/show/NCT04272697 Recruiting Imperial College London 2025-12-31